Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23292617 | 0.86 | MAPT (0.53) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL13327511 | 0.79 | VCAM1 (0.46) | MEN1KMT2AALDH1A1HSPB1MAPT | |
| SCHEMBL22966277 | 0.78 | TBXA2R (0.53) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL22069702 | 0.78 | HSPB1 (0.68) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL29351876 | 0.78 | HSPB1 (0.68) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL22069562 | 0.78 | PDE7A (0.74) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL641451 | 0.78 | TBXA2R (0.50) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL11095993 | 0.78 | VCAM1 (0.50) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL28443844 | 0.77 | TBXA2R (0.52) | TBXA2RMEN1KMT2AALDH1A1HSPB1 | |
| SCHEMBL7065552 | 0.76 | SLC6A4 (0.54) | TBXA2RMEN1KMT2AALDH1A1HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591775-A1 | Combinations comprising mtor inhibitors for treating cancer | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20120129881-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | BURKE GREGORY (US) | 2012-05-24 | — | — | US | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20090098137-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090023768-A1 | RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA | NOVARTIS AG (CH) | 2009-01-22 | — | — | US | disclosed |
| EP-2004163-A2 | COMBINATIONS COMPRISING MTOR INHIBITORS FOR TREATING CANCER | Novartis Pharma AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007124252-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023768-A1 | RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA | MTOR, MAPKAP1, RPS6KB2 | TBXA2R 4429/4885MEN1 862/4885KMT2A 1459/4885 |
| US-20090098137-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | MTOR, CDK4, MAPKAP1 | TBXA2R 4023/4885MEN1 820/4885KMT2A 2000/4885 |
| US-20120129881-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | MTOR, CDK4, MAPKAP1 | TBXA2R 4023/4885MEN1 820/4885KMT2A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.